Alex (@alexfldm) header
Alex (@alexfldm) profile picture

Keen Observer|Reader|Analyst

Brooklyn, NY
Joined June 2022
Photo by Alex (@alexfldm)Photo by Alex (@alexfldm)Photo by Alex (@alexfldm)Photo by Alex (@alexfldm)Photo by Alex (@alexfldm)Photo by Alex (@alexfldm)Photo by Alex (@alexfldm)Photo by Alex (@alexfldm)Photo by Alex (@alexfldm)Photo by Alex (@alexfldm)
Pinned Tweet
Key Data Points (as of early 2026)Industrial Production: Federal Reserve data shows manufacturing output grew at a 3.0% annualized rate in Q1 2026 (despite a minor 0.1% dip in March). Overall industrial production was up 0.7% year-over-year in March. ISM Manufacturing PMI: Expanded for the third straight month at 52.7 in March 2026 (above 50 signals growth), driven by strong new orders and production. "Stealth Boom" Details: Since January 2025, manufacturing jobs have fallen ~100,000 (-0.6% to ~12.59 million as of March 2026 per BLS), but production rose 2.3% and shipments 4.2%. This reflects automation and efficiency gains rather than contraction. Investment Surge: Private-sector commitments hit $1.595 trillion by April 2026, with factory construction and reshoring announcements up sharply. Employment has stabilized or ticked up modestly in recent months (e.g., +15,000 in March 2026), but the real job gains from these projects are still ramping (many facilities take 2–10 years to fully staff). The boom is real in economic output and future capacity, just not yet in headcount everywhere. m Sectors and Themes Driving the Trend: The revival is concentrated in high-value, strategic, and tech-enabled areas rather than low-wage assembly (e.g., apparel or basic consumer goods). Here's what's leading: Semiconductors & Electronics (biggest driver): Over $640 billion committed across 140+ projects in 30+ states. Production up 7.7% year-over-year (Q4 2025). AI/data center demand + CHIPS Act incentives are tripling domestic capacity by 2032 and creating hundreds of thousands of eventual jobs. Computers/electronics tied directly to the AI boom (semiconductors, networking, power/cooling gear). Clean Energy, EVs, Batteries & Electrical Equipment: ~$312 billion projected for automotive/EV manufacturing; clean energy investment quintupled to $14 billion/quarter. IRA incentives are pulling in solar components, batteries, and power infrastructure (transformers, switchgear). Data centers' massive electricity needs are a huge multiplier here. Pharmaceuticals & Life Sciences: Over $370 billion in 2025 pledges alone (e.g., Johnson & Johnson, Eli Lilly). Onshoring for supply-chain security post-pandemic. Aerospace, Defense & Transportation Equipment: Output up 28% year-over-year. Space boom (e.g., SpaceX), Boeing recovery, and national security priorities are boosting this. Overarching Themes:Reshoring & Supply-Chain Security: Tariffs, geopolitics, and lessons from COVID are driving companies to bring production stateside (or nearshore). This shows up in the freight data—less reliance on coastal imports. Policy Support: CHIPS Act, Inflation Reduction Act (IRA), tax reforms (e.g., full expensing, higher advanced manufacturing credits), and deregulation under the current administration. AI & Data Center Explosion: Creating outsized demand for chips, power equipment, and related manufacturing—described as a "sold-out" backlog in some segments. Automation & Smart Manufacturing: 80% of executives are investing heavily in AI/robots, analytics, and sensors. This explains why output is rising faster than jobs—productivity gains are key to the "stealth" nature. In short: Manufacturing is coming back in America, especially in advanced, strategic sectors that play to US strengths in innovation and high-tech production.
The most remarkable pattern is showing up in our high frequency freight data for the first time since we launched in 2018. The center of the country: the rust belt and and the industrial heartland is no longer just recipients of freight (imports) but actual producers of freight thanks to the surge in American manufacturing.
1
2
2
8
3,085
Replying to @fchollet @garrytan
Getting this amount of compute turned on, cooled and working reliably is incredibly hard. The cash shortage is also going to be nuts next year. Even cumulative industry delays of a few months between paying for compute and getting it reliable enough to generate revenue will mean hundreds of billions of incremental dollars just for working capital. Where will that come from?
38
Pre Selling 50% of a Greenfield Plant Before Day 1 of Commercial Production? Ratnaveer Precision Engineering Just Did Exactly That! 🚀⚡ In capital intensive industrial manufacturing, the biggest question mark for any greenfield project is always: "Will customers actually buy when the capacity goes live?" The company announced that it has formally secured long term supply agreements and confirmed orders covering nearly 50% of its total planned 5-line capacity (79.2 lakh sheets p.a.) for its upcoming FR-4 Copper Clad Laminate (CCL) facility in Vadodara, Gujarat De risking Demand in a High Stakes Import Substitution Space India currently imports >90% of its ₹5,000 Crore CCL demand (primarily from China and Taiwan) Securing confirmed orders for ~39.6 lakh sheets p.a. before commercial operations begin proves that domestic Printed Circuit Board (PCB) manufacturers are eager to switch to an indigenous, high reliability supplier Discussions for the remaining 50% capacity are already in advanced stages with leading PCB fabricators Management explicitly stated that these baseline figures do not reflect the recent surge in global and domestic CCL pricing With prevailing market realizations running significantly higher and half the capacity already locked in, Ratnaveer confirmed that upwardly revised revenue and profit guidance will be announced following initial order execution Disclaimer Not a stock recommendation
From Precision Fasteners to Electronics Substrates: Ratnaveer Precision Engineering Ltd Delivers a Blockbuster Q2 FY27! Can a traditional industrial manufacturer successfully pivot into high tech electronic materials while accelerating its core engine? Ratnaveer Precision Engineering Limited just dropped its Q2 FY27 results, proving that manufacturing discipline paired with import substitution megatrends can drive serious operating leverage Here is a breakdown of the performance, numbers, and strategic pivot Q2 FY27 Highlights (Consolidated) Revenue from Operations: ₹387.24 Cr (+35.46% YoY vs. ₹285.87 Cr in Q2 FY26) EBITDA: ₹42.16 Cr (+38.94% YoY vs. ₹30.35 Cr) EBITDA Margin: 10.89% (up 27 bps YoY) Profit After Tax (PAT): ₹24.07 Cr (+55.92% YoY vs. ₹15.43 Cr) PAT Margin: 6.21% (expanding 81 bps YoY) For H1 FY27, top line touched ₹701.87 Cr (+27.50% YoY), while net profit surged 39.24% YoY to ₹42.31 Cr Mr. Vijay R. Sanghavi, Managing Director, highlighted the operational momentum: "Revenue from operations grew 35.46% YoY to ₹3,872.37 million, while EBITDA increased 38.94% to ₹421.62 million and PAT grew 56.14% to ₹240.97 million in Q2 FY27. We are making steady progress on our integrated FR-4 Copper Clad Laminate project, which has achieved approximately 75% completion, with machinery expected by mid November 2026. With India's domestic CCL market largely dependent on imports and increasing demand from electronics, EVs, telecom and defence sectors, we see significant long term opportunities in this segment Core Engineering Business is Accelerating Ratnaveer is India's 1 exporter of stainless steel washers (serving 31 countries) and has successfully integrated forward into industrial fasteners (nuts & bolts) and tubes. Top line growth jumped from 18.9% in Q1 to 35.5% in Q2. Backward integrated scrap recycling via in house induction furnaces and captive solar power keeps margins resilient against raw material price swings The PCB Substrate Growth Vector (FR-4 CCL) Ratnaveer is setting up India’s first integrated FR-4 grade Copper Clad Laminate (CCL) facility in Vadodara The Problem: Over 90% of India's ₹5,000 Cr CCL demand is imported The Solution: Ratnaveer’s facility directly addresses domestic PCB fabricators for EVs, 5G telecom, defence, and semiconductor packaging Status: 75% completed; main machinery shipments arriving by mid November 2026 for immediate erection and trial runs Policy Tailwinds: Approved under the Central Govt’s ECMS (₹338 Cr scheme) and the Gujarat Electronics Policy, unlocking ~50% capex subsidies and a 7% interest subvention Balance Sheet De risked with ₹330 Cr Rights Issue The Bigger Picture: The Road to ₹2,500 Cr Management has laid out a clear roadmap to reach ₹2,500 Crore in consolidated revenues over the next 2.5 to 3 years Core Stainless/Fasteners Scaling towards ₹1,750–1,800 Cr CCL Division: Adding ₹750+ Cr at ~20% EBITDA margin across 5 planned lines. Target Net Profit: ₹240 to ₹262 Crore (blended PAT margin ~10%) Disclaimer Not a stock recommendation
1
143
Ashton Kutcher’ın kurucu ortakları arasında yer aldığı girişim sermayesi şirketi Sound Ventures’ın yakın dönemde gerçekleştirdiği yatırımları aşağıda görebilirsiniz. Şirketin (track record) oldukça başarılı bir tablo ortaya koyuyor. Elbette, bu başarı hikâyelerinin yanında beklentileri karşılamayan veya istenen getiriyi sağlayamayan yatırımlarının da bulunduğunu göz ardı etmemek gerekiyor. Şirketin websitesi: soundventures.com/ Oldukça sade 🙂
4
53
8,016
Is the Indian cooling and RAC sector approaching a major margin inflection? ❄️📈 Over the past few quarters, Room AC and consumer durable companies have been caught in a challenging squeeze strong double digit volume growth, but compressed margins due to an 18% surge in input costs that couldn't be fully passed on to consumers. Now, a reversal in commodity dynamics is reshaping the setup Copper is down ~11% from its recent peak of $14,870/mt. Aluminium has touched CY26 lows. In a typical RAC, raw materials primarily copper, aluminium, steel, and plastics account for over 52% of the total Bill of Materials (BOM). Volume Growth vs. Margin Squeeze Q2 FY27 delivered robust primary volume growth (+35% to +42% YoY) across the industry, driven by an extended summer and early festival stocking However, profitability was heavily compressed Blue Star’s Unitary Products EBIT margin dropped to 2.3% (vs. 6.2% YoY) Voltas saw a mismatch between an 18% cost jump and ~14% price hikes. Amber Enterprises absorbed a quarterly indexation lag, passing on only ~50% of cost hikes in Q2. The core issue An unrecovered 5% pricing gap While costs surged 18%, brands could only pass on ~13% (including the recent 5% hike in October) due to intense competition and domestic capacity standing at 1.7x to 2.0x demand Why Falling Metal Prices Change the Equation With copper and aluminium retreating, the dynamics shift favorably for H2 FY27 and FY28: The 5% Deficit Closes Organically Brands rarely cut printed consumer prices mid season Why Falling Metal Prices Change the Equation With copper and aluminium retreating, the dynamics shift favorably for H2 FY27 and FY28 The 5% Deficit Closes Organically Brands rarely cut printed consumer prices mid season The October 5% price hike, coupled with falling metal costs, effectively restores gross margins by 150–200 bps Commercial Refrigeration Revival Commercial units require 24%–25% price increases due to heavy steel and plastic content Falling raw material costs lower barrier prices for institutional FMCG, QSR, and quick commerce clients The Outsourcing Inflection Facing excess capacity, branded OEMs are actively raising outsourced entry level RAC manufacturing from 15% to up to 30% This provides structural volume tailwinds for ODMs like Amber, PGEL, and EPACK. AI & Data Centers Beyond consumer appliances, the cooling conversation has expanded into enterprise infrastructure. High density AI servers generate significant heat loads, requiring specialized high velocity cooling Blue Star commands a ~30% domestic market share in Data Center MEP contracting. Its Data Center revenue is guided to scale from ₹1,000 Cr in FY26 ➔ ₹2,000 Cr in FY27E ➔ ₹4,000 Cr by FY30 These projects deliver 10%–12% standalone EBIT margins with 8–9 month turnarounds and favorable working capital transforming Blue Star into a netcash business (₹289 Cr in H1 FY27) Branded OEMs (Blue Star, Voltas) offer an attractive risk reward profile, as retained price hikes and deflating metal costs drive operating leverage. Blue Star stands out for its business mix a consumer turnaround coupled with an expanding Data Center moat and strong balance sheet health ODMs (Amber, PGEL) remain long term compounders from increased OEM outsourcing though current multiples of 42x–46x FY28E reflect much of that growth. EPACK Durable presents a mispriced turnaround candidate, benefiting from backward integration into copper tubing. With the industry entering its crucial pre summer stocking window, margin recovery could prove to be the primary narrative for cooling players in early 2027. Disclaimer Not a stock recommendation
1
3
440
Falling base metal prices is a clear positive margin catalyst for IKIO Technologies.
IKIO is now trading at an even deeper discount to the sector offering substantially higher gross margins and virtually zero net debt
167
Falling copper price is a net positive for Ratnaveer Precision Engineering.
From Precision Fasteners to Electronics Substrates: Ratnaveer Precision Engineering Ltd Delivers a Blockbuster Q2 FY27! Can a traditional industrial manufacturer successfully pivot into high tech electronic materials while accelerating its core engine? Ratnaveer Precision Engineering Limited just dropped its Q2 FY27 results, proving that manufacturing discipline paired with import substitution megatrends can drive serious operating leverage Here is a breakdown of the performance, numbers, and strategic pivot Q2 FY27 Highlights (Consolidated) Revenue from Operations: ₹387.24 Cr (+35.46% YoY vs. ₹285.87 Cr in Q2 FY26) EBITDA: ₹42.16 Cr (+38.94% YoY vs. ₹30.35 Cr) EBITDA Margin: 10.89% (up 27 bps YoY) Profit After Tax (PAT): ₹24.07 Cr (+55.92% YoY vs. ₹15.43 Cr) PAT Margin: 6.21% (expanding 81 bps YoY) For H1 FY27, top line touched ₹701.87 Cr (+27.50% YoY), while net profit surged 39.24% YoY to ₹42.31 Cr Mr. Vijay R. Sanghavi, Managing Director, highlighted the operational momentum: "Revenue from operations grew 35.46% YoY to ₹3,872.37 million, while EBITDA increased 38.94% to ₹421.62 million and PAT grew 56.14% to ₹240.97 million in Q2 FY27. We are making steady progress on our integrated FR-4 Copper Clad Laminate project, which has achieved approximately 75% completion, with machinery expected by mid November 2026. With India's domestic CCL market largely dependent on imports and increasing demand from electronics, EVs, telecom and defence sectors, we see significant long term opportunities in this segment Core Engineering Business is Accelerating Ratnaveer is India's 1 exporter of stainless steel washers (serving 31 countries) and has successfully integrated forward into industrial fasteners (nuts & bolts) and tubes. Top line growth jumped from 18.9% in Q1 to 35.5% in Q2. Backward integrated scrap recycling via in house induction furnaces and captive solar power keeps margins resilient against raw material price swings The PCB Substrate Growth Vector (FR-4 CCL) Ratnaveer is setting up India’s first integrated FR-4 grade Copper Clad Laminate (CCL) facility in Vadodara The Problem: Over 90% of India's ₹5,000 Cr CCL demand is imported The Solution: Ratnaveer’s facility directly addresses domestic PCB fabricators for EVs, 5G telecom, defence, and semiconductor packaging Status: 75% completed; main machinery shipments arriving by mid November 2026 for immediate erection and trial runs Policy Tailwinds: Approved under the Central Govt’s ECMS (₹338 Cr scheme) and the Gujarat Electronics Policy, unlocking ~50% capex subsidies and a 7% interest subvention Balance Sheet De risked with ₹330 Cr Rights Issue The Bigger Picture: The Road to ₹2,500 Cr Management has laid out a clear roadmap to reach ₹2,500 Crore in consolidated revenues over the next 2.5 to 3 years Core Stainless/Fasteners Scaling towards ₹1,750–1,800 Cr CCL Division: Adding ₹750+ Cr at ~20% EBITDA margin across 5 planned lines. Target Net Profit: ₹240 to ₹262 Crore (blended PAT margin ~10%) Disclaimer Not a stock recommendation
1
277
Breaking: Stanley Druckenmiller just filed his Q3 13F He dumped every share of Sandisk, AMD and Google and bought SpaceX Here’s everything you need to know about his recent 13F Top 10 positions: • Natera $NTRA • Seagate $STX • Amazon $AMZN • Fox $FOXA • YPF $YPF • Unity $U • Sea $SE • iShares Brazil $EWZ • Insmed $INSM • Amazon $AMZN [Call] New positions: • Somnigroup $SGI • Newmont $NEM • Barrick $B • Agnico Eagle $AEM • Western Digital $WDC • AppLovin $APP • SpaceX $SPCX • TTM Technologies $TTMI • Humana $HUM • Palantir $PLTR Full exits: • Alphabet $GOOGL • United Airlines $UAL • Sandisk $SNDK • Delta $DAL • DR Horton $DHI • AMD $AMD • S&P 500 $SPY [Call] • Russell 2000 $IWM [Call] Biggest trims: • Taiwan Semiconductor $TSM: sold 94% • CRH $CRH: sold 71% • STMicro $STM: sold 48% Summary: He sold out of 48 positions, bought gold miners, and put 29.2% of his $4,470,000,000 portfolio into Natera
68
Integrated, low cost producers with captive resources and aggressive volume expansions. Sandur Manganese & Iron Ores Limited Merchant Miner ➡️ Integrated Specialty Metals Platform For decades, SANDUMA was viewed simply as a regional merchant miner that narrative is now obsolete. Following the acquisition of Royal Sandur Metals (formerly Arjas Steel), SANDUMA is now among India's top 5 producers of Special Bar Quality (SBQ) automotive and alloy steels. It operates a completely synchronized ecosystem Captive high grade iron ore and manganese mining ➡️ captive coke ovens & waste heat power (WHRB) ➡️ ferroalloys ➡️ specialty alloy steel Q2 FY27 Results Margin Expansion in Full Display While the broader sector frets over margins, SANDUMA Q2 FY27 results just confirmed immense operational leverage Consolidated Revenue: ₹1,506 Cr (+22.2% YoY) Consolidated EBITDA: ₹391 Cr (+36.7% YoY) with margins expanding to 26.0% (Standalone mining EBITDA margin: 44% Consolidated PAT: ₹261 Cr (+88.1% YoY) H1 FY27 Diluted EPS: ₹10.03 (Tracking ~₹20+ annualized) Cash Flow from Operations: ₹491 Cr generated in just 6 months As Managing Director Bahirji A. Ghorpade noted: “Q2FY27 has been another healthy quarter, with robust mining volumes despite the seasonally slow monsoon period and continued strong performance from Royal Sandur Metals. The approved capacity expansion at our Punjab steel plant and our foray into Medical Devices mark concrete steps towards new frontiers...” SANDUMA saw steel sales realisations jump to ₹78,422/T (+5% QoQ) mirroring exactly what Weldbend reported regarding producers favoring high margin alloy products over commodity steel. Weldbend’s warning that "steel producers are fully booked until 2028 and allocating toward high margin products" isn't just an industry anecdote it's the macro catalyst that powers the next phase of the specialty metals cycle. With SANDUMA balance sheet de levered, environmental approvals in hand to more than double iron ore mining, and specialty steel realizations steadily climbing. SANDUMA might be a deep value Disclaimer: For research and educational purposes only. Not investment advice.
A Global Steel shortage through 2028, a European gas crisis, and the Strait of Hormuz shock Who actually wins in India’s metals and Industrial supply chain? A recent operational notice from US piping giant Weldbend paints a stark picture of the global industrial macro Primary & offshore steel mills are fully booked through 2027/2028. European gas storage is near historic lows, putting extreme pressure on energy intensive European mills. Middle East LNG transit disruptions via the Strait of Hormuz are driving global fuel, tooling, and logistics costs sharply higher. Steelmakers are actively rationing raw steel to pivot into higher margin product categories. When primary steel and industrial energy become scarce, not all metals companies are created equal. The Value Chain Reality Upstream Moats vs. Downstream Squeezes The Upstream Winners (Ore + Captive Power) Smelting ferro alloys and making direct reduced iron (DRI) is intensely power hungry. When European energy costs soar European smelters curtail production. Indian integrated players with captive waste heat recovery (WHRB) power and captive mines don’t just survive they capture global export arbitrage with zero cost push inflation. The Downstream Converters Secondary fabricators who rely on buying merchant hot rolled coils (HRC) face delivery delays and input cost inflation, unless they have downstream pricing power, value added products, and strong balance sheets.
1
4
423
How Manaksia Steels Anticipated the Global Squeeze While global downstream processors are scrambling to secure allocations. Indian specialty coated manufacturer Manaksia Steels Ltd just reported its Q2 FY27 results showcasing how proactive supply chain engineering turns global bottlenecks into record profits Consolidated Revenue: ₹419.53 Cr (+59.7% YoY) Consolidated EBITDA: ₹38.21 Cr (+185.4% YoY) Consolidated PAT: ₹24.20 Cr (+437.4% YoY) H1 FY27 PAT: ₹46.84 Cr surpassing the entire net profit generated in FY26 (₹39.92 Cr) Solving the 14 Month Feedstock Bottleneck via In House Backward Integration Weldbend noted that primary mills are reallocating raw steel away from basic conversion. Manaksia's management flagged the exact same bottleneck: "availability and consistency of supply from external sources remain challenging at times" The Solution Instead of remaining dependent on external mills MSL is setting up its own 250,000 MTPA 6 Hi Cold Rolling Mill at Haldia (~₹100 Cr capex) expanding cold rolling capacity to 350,000-370,000 MTPA by Q4 FY28 to secure in house substrate supply and protect conversion spreads Riding the "Value Add" Wave Rather than Fighting It While pure fabricators get squeezed MSL shifted its mix toward the highest margin coated segments Aluzinc / Galvalume line (110,200 TPA): Ramped up to >85% capacity utilisation within its first year. Colour Coating Line II (CCL II): Adding 72,000-90,000 TPA to scale pre painted capacity to 150,000 TPA Brand Pricing Power: Selling branded architectural products (Austrang, 5 Star Super Colour) that command pricing premiums, keeping EBITDA margins robust at 9.1%-10.0% De Risking Working Capital & Logistics Against Global Volatility No More Import Traps: MSL shifted away from bulk import shipments (which previously tied up 20,000 MT of capital over 3-5 months) to monthly domestic sourcing, cutting inventory tenure from 88 days down to ~54 days and shielding the balance sheet from Middle East maritime freight spikes Port Proximity The Haldia facility's direct proximity to the port enables coastal domestic distribution and cost effective raw material imports when international spreads are advantageous. Disclaimer Not a stock recommendation
A Global Steel shortage through 2028, a European gas crisis, and the Strait of Hormuz shock Who actually wins in India’s metals and Industrial supply chain? A recent operational notice from US piping giant Weldbend paints a stark picture of the global industrial macro Primary & offshore steel mills are fully booked through 2027/2028. European gas storage is near historic lows, putting extreme pressure on energy intensive European mills. Middle East LNG transit disruptions via the Strait of Hormuz are driving global fuel, tooling, and logistics costs sharply higher. Steelmakers are actively rationing raw steel to pivot into higher margin product categories. When primary steel and industrial energy become scarce, not all metals companies are created equal. The Value Chain Reality Upstream Moats vs. Downstream Squeezes The Upstream Winners (Ore + Captive Power) Smelting ferro alloys and making direct reduced iron (DRI) is intensely power hungry. When European energy costs soar European smelters curtail production. Indian integrated players with captive waste heat recovery (WHRB) power and captive mines don’t just survive they capture global export arbitrage with zero cost push inflation. The Downstream Converters Secondary fabricators who rely on buying merchant hot rolled coils (HRC) face delivery delays and input cost inflation, unless they have downstream pricing power, value added products, and strong balance sheets.
3
257
A Global Steel shortage through 2028, a European gas crisis, and the Strait of Hormuz shock Who actually wins in India’s metals and Industrial supply chain? A recent operational notice from US piping giant Weldbend paints a stark picture of the global industrial macro Primary & offshore steel mills are fully booked through 2027/2028. European gas storage is near historic lows, putting extreme pressure on energy intensive European mills. Middle East LNG transit disruptions via the Strait of Hormuz are driving global fuel, tooling, and logistics costs sharply higher. Steelmakers are actively rationing raw steel to pivot into higher margin product categories. When primary steel and industrial energy become scarce, not all metals companies are created equal. The Value Chain Reality Upstream Moats vs. Downstream Squeezes The Upstream Winners (Ore + Captive Power) Smelting ferro alloys and making direct reduced iron (DRI) is intensely power hungry. When European energy costs soar European smelters curtail production. Indian integrated players with captive waste heat recovery (WHRB) power and captive mines don’t just survive they capture global export arbitrage with zero cost push inflation. The Downstream Converters Secondary fabricators who rely on buying merchant hot rolled coils (HRC) face delivery delays and input cost inflation, unless they have downstream pricing power, value added products, and strong balance sheets.
This issue has been addressed by few Indian business. Interesting to keep a track on valuation in such scenarios
1
1
846
Good to see IGIL FCF margins being recognised by the market.
61% EBITDA margin, cash compounding International Gemological Institute Limited (IGIL) Q2 FY27 While the market often debates the diamond retail cycle, IGI operates an asset light, mission critical utility business model As CEO Tehmasp Printer put it “An IGIL certificate makes a lab grown diamond a diamond. Otherwise, without certification, it can be considered just as a piece of glass" High Operating Leverage Across the Board (Q2 FY27 YoY) Volumes: 4.35 Million reports (+26% YoY) Certification Revenue: ₹3,875 Mn (+32% YoY) Consolidated EBITDA: ₹2,445 Mn (+39% YoY) with margins expanding to 61.4% (+340 bps) PAT: ₹1,858 Mn (+43% YoY) with a net margin of 46.7% Annualized PAT run rate of ~₹720–740 Cr Indian growers are mastering CVD technology to produce larger carat weights (even certifying single stones up to 75 carats) At the same time, the acquisition of American Gemological Laboratories (AGL) has opened the high ticket coloured gemstone segment. Market has definitely been sleeping on this business..!! Disclaimer: Not a stock recommendation
1
273
Around 2017, SoftBank built a roughly $4 billion stake in NVIDIA. In early 2019, Softbank sold the entire holding for about $3.3–3.6 billion, locking in a solid profit at the time (roughly $2.6 billion gain). That sale came years before ChatGPT and the subsequent explosive rise in NVIDIA’s share price. Had SoftBank held those original shares, they would later have been worth well over $100–150 billion by most estimates.⁠ Masayoshi Son has been bad with timing
1
125
This issue has been addressed by few Indian business. Interesting to keep a track on valuation in such scenarios
Hugely interesting development this week. Snippet from this week FFTT by @LukeGromen
1
1
298
Is this India’s most profitable pure play API & CDMO player flying under the radar? When investors think about high margin pharmaceutical manufacturing in India, big CDMO names usually dominate the conversation. But Alivus Life Sciences Limited (formerly Glenmark Life Sciences) just delivered a masterclass in operational excellence for Q2 FY27 The Numbers at a Glance (Q2 FY27) Revenue from Operations: ₹682.0 Cr (+16.0% YoY / +6.5% QoQ) Gross Margin: 64.4% (expanded by +670 bps YoY) EBITDA: ₹285.1 Cr (+47.0% YoY) with an EBITDA margin of 41.8% (Adjusted EBITDA margin stood at ~39.5% excluding one offs) Profit After Tax (PAT): ₹196.8 Cr (+51.3% YoY) PAT Margin: 28.9% p EPS: ₹16.02 for the quarter (H1 FY27 EPS at ₹29.06) Cash & Liquidity: ₹1,011.6 Cr in liquid cash & short term investments with Zero Debt ROICE: Surged to ~34% In the words of MD & CEO, Dr. Yasir Rawjee: “Q2FY27 was another strong quarter for us, with revenue growing 16.0% YoY, supported by healthy demand across all key markets and robust contributions from recent launches. Non GPL business momentum was maintained, while CDMO business saw a meaningful pick up during the quarter. The improving business mix and greater operating efficiencies also translated into better underlying profitability.” Key Takeaways Behind the Transformation 1. The De Risking Strategy Has Delivered (Non-GPL at 79%) For years, critics pointed to customer concentration with Glenmark Pharma (GPL). That narrative is now largely obsolete Non GPL revenue grew +20.8% YoY across North America, Europe, Japan, and LATAM, now contributing 79% of total sales GPL business is expected to recover seasonally in H2, bringing full year GPL revenue to ₹700 – ₹750 Cr 2. CDMO Growth is Scaling Rapidly Segment revenue surged +79.9% YoY and +32.3% QoQ to ₹50 Cr CFO Tushar Mistry confirmed the target: “We have been guiding that we will double the business from where it is today in next 3 to 4 years time, which would effectively contribute to about between 12% to 15% of the overall revenues.” 3. Game Changing Capacity Coming Online in FY27 (+51% Capacity Jump) Alivus is expanding its total reactor capacity from 1,424 KL to 2,150 KL by end of FY27E (reaching 2,690 KL by FY29E) Dahej Brownfield: +160 KL (operational Q3 FY27) Ankleshwar Brownfield: +100 KL (operational Q4 FY27) Solapur Greenfield: Phase 1 (~340 KL) in Q3 FY27 and Phase 2 (~125 KL) in Q4 FY27 Entire capex (~₹540 Cr in FY27) is 100% funded through internal cash flows 4. High Entry Barrier Pipeline ("API+") HPAPI Pipeline: 30 molecules addressing a massive $86 Bn TAM (14 validated, commercial inflection begins late FY28) Iron Complexes: 4 products targeting $2.9 Bn TAM Flow Chemistry Tech: First commercialized flow chemistry molecule slashed COGS by >50% compared to batch processing Management Guidance & Outlook FY27 Top line Re iterated 10% to 12% revenue growth FY27 EBITDA Margin Confidently guided to 35% to 36% FY28 Floor Margin Even in a worst case scenario, Dr. Rawjee guided a margin floor of 30% to 32%, while aiming to sustain current high 30s momentum. Alivus currently trades at ~24x FY27E EPS (guided ₹61.5) and ~21x FY28E EPS (projected ₹70.1). TTM EV/EBITDA of ~17x, backed by ₹1012 Cr in net cash Disclaimer Not a stock recommendation
2
2
17
1,823
Supriya Lifescience Ltd. Q2FY27 result While the topline crossed the ₹200 crore quarterly mark, operating margins experienced a sharp reality check. Revenue: ₹206.3 Cr (+3.2% YoY, +8.7% QoQ) | H1 Revenue: ₹396.0 Cr (+14.8% YoY) EBITDA: ₹45.4 Cr (-37.5% YoY) | EBITDA Margin: 22.0% (vs 36.4% in Q2 FY26 & 25.0% in Q1 FY27) PAT: ₹29.3 Cr (-42.0% YoY, +21.7% QoQ) | PAT Margin: 14.2% Balance Sheet: Zero debt with ~₹182.5 Cr in liquid cash/investment After guiding for a structural 33–35% margin corridor in August, management was transparent in attributing the margin contraction to three simultaneous headwinds Regulatory Shifts in LATAM Policy changes slowed dispatches of high margin products to LATAM (revenue mix dropped from 21% to 12%), forcing a temporary shift in volumes toward lower margin, semi regulated markets. Ambernath Facility Drag The newly commissioned finished dosage (FDF) plant is in its active ramp up phase. Fixed overheads, quality team expansion, and trial runs are hitting the P&L ahead of commercial revenue scale. Persistent Solvent & Input Inflation Geopolitical conflicts and freight disruptions kept raw material and solvent costs elevated, pulling gross margins down ~650 bps YoY to 65.6%. Despite near term margin volatility, Supriya achieved major strategic milestones during the quarter Commercial Formulation Debut Successfully commercialised and launched two new liquid inhalation anesthetic formulations from the Ambernath site, with an initial exhibit batch order bagged for RoW markets. Semaglutide / GLP-1 Breakthrough Developed and filed a patent for a novel oral Semaglutide tablet formulation, and is actively collaborating with a leading Indian generics major for GLP-1 portfolio development and supply. Regulated Market Inroads Europe surged to 43% of total revenues (vs 37% last year), while North America expanded to 5% as validation batches for its 22 US DMF filings gained traction. Working Capital Discipline Trade receivables were aggressively collected, dropping from ₹219 Cr in March to ₹126 Cr in September releasing nearly ₹94 Cr of cash back into the business. Topline Goal Management’s stated target of ₹1,000 Cr for FY27 implies delivering ₹604 Cr in H2 (~₹302 Cr per quarter). While H2 is seasonally stronger, reaching ₹1,000 Cr without large, lumpy CDMO licensing dispatches will be a steep climb. Operating Leverage Ambernath’s opex drag will only reverse once commercial volumes ramp and unit costs are absorbed across its five operational FDF lines. Triggers to Track Over the Next 60 Days The November 2026 EU-GMP Audit at the Ambernath formulations site the critical regulatory passport for European CMO/CDMO contracts. Execution of the Anesthetic CDMO Contract, where management previously indicated they were close to finalizing a major term sheet. Margin Recovery Trajectory Pace of customer price pass throughs in H2.
Supriya Lifescience’s Q1 FY27 results were a mix of strong underlying growth and one off operational headwind Q1 FY27 snapshot Revenue: ₹190 cr, up 31% YoY (vs ₹145 cr) despite disruptions. Management highlighted that demand remains strong and that ₹30–35 cr of sales were deferred due to water issues. EBITDA: ₹47 cr, down 8% YoY (vs ₹52 cr); margin at 25%. PAT: ₹24 cr (vs ₹35 cr); PAT margin 12.7%. Exports: 81% of revenue; diversified across Asia (39%), Europe (35%), LATAM (20%). Backward integration: ~72% of revenues from fully integrated products, reinforcing cost and supply resilience. Water scarcity at Lote MIDC First time event driven by delayed monsoon and low Koina river levels. Caused 15–20 days of disruption and lost production/sales of ₹30–35 cr. Management: “Water issue is already resolved… getting ample water… I don’t think this would be a recurrent issue in quarter two.” Mitigation: exploring water recycling for utilities (cooling towers etc.), while respecting API GMP constraints. Power cost spike from solar policy change in Maharashtra Joint MD pegged ~₹8 cr EBITDA impact from higher power/fuel costs. CFO added ₹4.5–5 cr of retrospective levy recognised in Q1. Management: intends to pass incremental cost to customers over time, given PO based pricing; also noted an ongoing industry legal challenge by solar associations. Management’s core message: The margin hit is seen as “mostly temporary in nature”. Excluding water and power shocks, profitability would have been broadly in lne with their long term guidance. ₹1,000 cr revenue target by FY27 remains “firmly on track” (though growth may be non linear). EBITDA margin guidance of 33 - 35% over the next 3 - 4 years. tweaked operations to protect FY27 A planned large maintenance shutdown across Blocks A–D has been split into phased, smaller interventions, specifically to avoid another hit to Q2 production after Q1’s lost volumes.
1
7
547
IKIO is now trading at an even deeper discount to the sector offering substantially higher gross margins and virtually zero net debt
1
1
1
416
Since many X users are interested in Peptide growth story Shilpa is expanding peptide and GLP-1 platform Peptides sit within the Specialty CDMO umbrella (which bundles API CDMO, polymers, and peptides). Specialty CDMO accounted for ₹62 Cr out of ₹1,007 Cr total revenue (~6% of sales). Peptides currently contribute a low single digit percentage of overall business. However, that baseline is set to shift as the company completes its multi year capital deployment cycle. Unlike players restricted purely to chemical synthesis or external sourcing, Shilpa has developed integrated technical proficiencies Dual Route Synthesis One of the few Indian manufacturers mastering both Solid Phase Peptide Synthesis (SPPS) and semi synthetic recombinant fermentation + chemical coupling routes. Commercial Generic Precedents Established regulatory track record with European CEP and global DMF approvals for complex peptides like Desmopressin and Octreotide Acetate, alongside scale up in Teriparatide. Shilpa is executing a fully backward integrated strategy in GLP-1 Semaglutide (Ozempic / Wegovy) API validation batches completed via both synthetic and semi-synthetic pathways. US DMF ready for filing in 1H FY27. Formulations developed for both Subcutaneous Injectable Pens (PFS) and Oral Solid (tablets). Exhibit batches are complete; stability testing is underway with partnering discussions active across non US markets for FY28–FY29 generic rollouts. Liraglutide Validation complete, DMF readied, and captive formulations prepared for global generic markets. Tirzepatide Lab scale development initiated to support the next wave of multi receptor agonists. Peptide chemistry requires specialized, highly automated containment and synthesis infrastructure Shilpa is currently building a dedicated commercial peptide block at its Raichur campus, slated for commissioning by end FY27. Engineered as one of India’s largest automated solid phase synthesis facilities, it is custom built to handle commercial scale GLP-1s, High Potency APIs (HPAPIs), and innovator CDMO mandates. Peptide Drug Conjugates (PDCs) Shilpa is also leveraging peptides in targeted therapeutics Gate2Brain Partnership (G2B-002) Shilpa holds a 30.4% strategic equity stake and serves as exclusive CMC and regulatory partner for an Orphan Drug designated pediatric glioblastoma therapy. The asset utilizes a proprietary brain shuttle peptide (MiniAp4) conjugated to an oncology payload (SN-38) to traverse the blood brain barrier combining Shilpa’s complex payload chemistry with advanced peptide delivery. With dedicated capacity commissioning by end FY27 and global Semaglutide filings advancing, this segment is positioned to transition from an R&D and pilot line into a meaningful, high margin commercial pillar starting in FY28.
Shilpa Medicare: The "Harvesting Phase" Delivers Another Record Quarter Q2FY27 Analysis Shilpa Medicare Limited sustained operating momentum across all three business divisions. Topline Crosses ₹1,000 Cr Q2 EBITDA grew 37% YoY to ₹151 Cr, with margins at 28.1% Q2 PAT reached ₹79 Cr (+80% YoY) with effective tax normalizing to ~24%. PAT nearly doubled to ₹180 Cr Operating Cash Flow (CFO) reached ₹292 Cr (1.6x of reported PAT). Net Debt / EBITDA remains low at 1.3x Formulations (+51% YoY in Q2 to ₹210 Cr) Ex licensing, base formulations surged 87% YoY. Europe doubled to ₹82 Cr, supported by limited-competition oncology assets (Nilotinib/Axitinib). US climbed to ₹35 Cr (+75% YoY), driven by 505(b)(2) RTU injectables. India surged 122% YoY to ₹20 Cr, led by commercial traction from NorUDCA (Noduca™). API & Specialty CDMO (+24% YoY non-captive to ₹254 Cr) Core API volumes remain stable, Specialty CDMO grew 36% YoY to ₹34 Cr, with 6 late stage programs in Phase III/Registration. Biologics (+160% YoY to ₹65 Cr): Progressing via licensing milestones, CDMO client deliveries, and supply agreements. Unicycive (OLC): NDA resubmitted with secondary vendor CMC data. US FDA set a formal PDUFA target action date of March 25, 2027. Dedicated commercial block is fully commissioned. Rotigotine Transdermal Patch: EMA approved European commercial launch slated for 2H FY27 US ANDA filed. OERIS™ (Ondansetron ER Injection): SEC marketing authorization granted India launch in 2H FY27, EU Phase III starting 2H FY27. European Oncology Filings: Submissions completed for Nab Paclitaxel (Abraxane), Enzalutamide (Xtandi), and Abiraterone 1g. Biologics & Novel Platforms: Nivolumab: Phase I/III human trials underway with Orion as EU partner. Recombinant Human Albumin (rHA): Global Phase III trials (India & EU) commencing in 2H FY27. ADCs: Integrated GMP facility in Dharwad commissioned; Phase I for first ADC biosimilar planned for 1H FY28.
1
8
650
Shilpa Medicare: The "Harvesting Phase" Delivers Another Record Quarter Q2FY27 Analysis Shilpa Medicare Limited sustained operating momentum across all three business divisions. Topline Crosses ₹1,000 Cr Q2 EBITDA grew 37% YoY to ₹151 Cr, with margins at 28.1% Q2 PAT reached ₹79 Cr (+80% YoY) with effective tax normalizing to ~24%. PAT nearly doubled to ₹180 Cr Operating Cash Flow (CFO) reached ₹292 Cr (1.6x of reported PAT). Net Debt / EBITDA remains low at 1.3x Formulations (+51% YoY in Q2 to ₹210 Cr) Ex licensing, base formulations surged 87% YoY. Europe doubled to ₹82 Cr, supported by limited-competition oncology assets (Nilotinib/Axitinib). US climbed to ₹35 Cr (+75% YoY), driven by 505(b)(2) RTU injectables. India surged 122% YoY to ₹20 Cr, led by commercial traction from NorUDCA (Noduca™). API & Specialty CDMO (+24% YoY non-captive to ₹254 Cr) Core API volumes remain stable, Specialty CDMO grew 36% YoY to ₹34 Cr, with 6 late stage programs in Phase III/Registration. Biologics (+160% YoY to ₹65 Cr): Progressing via licensing milestones, CDMO client deliveries, and supply agreements. Unicycive (OLC): NDA resubmitted with secondary vendor CMC data. US FDA set a formal PDUFA target action date of March 25, 2027. Dedicated commercial block is fully commissioned. Rotigotine Transdermal Patch: EMA approved European commercial launch slated for 2H FY27 US ANDA filed. OERIS™ (Ondansetron ER Injection): SEC marketing authorization granted India launch in 2H FY27, EU Phase III starting 2H FY27. European Oncology Filings: Submissions completed for Nab Paclitaxel (Abraxane), Enzalutamide (Xtandi), and Abiraterone 1g. Biologics & Novel Platforms: Nivolumab: Phase I/III human trials underway with Orion as EU partner. Recombinant Human Albumin (rHA): Global Phase III trials (India & EU) commencing in 2H FY27. ADCs: Integrated GMP facility in Dharwad commissioned; Phase I for first ADC biosimilar planned for 1H FY28.
Shilpa Medicare Harvest Phase Is Real And Now Biologics Are Joining the Party Q1FY27 Strategic highlights APIs 3 advanced NCE programs targeted for FY28 commercialisation, plus 15 new oncology generics under validation. Formulations Rotigotine transdermal patch filed in the US (EU launch already slated for Q1 FY27). Oncology filings lined up for FY28: Abrexin, Enzalutamide, Abiraterone. Biologics & albumin Nivolumab biosimilar co development & supply deal with Orion for Europe (originator did ~USD 4.1 bn in EU sales in 2025). Recombinant Human Albumin has entered human clinical studies in FY27. Management is clear that heavy investing is largely behind them. The focus now is on converting those investments ADC facility, peptide plants, biosimilars, Nor UDCA, Unicycive NCE into sustained growth and high quality margins. It’s evolving into a complex formulations, biologics + CDMO platform with global grade partners.
1
1
6
1,246
The regime shift means it’s going to be very easy for investors to get burnt applying frameworks that worked for the first part of the cycle to the next. Our 10th State of the Themes is about how we intend to avoid that. citriniresearch.com/p/state-…
1
95